UK cost agency turns down Sanofi bowel cancer drug

[riky]

UK cost agency turns down Sanofi bowel cancer drug

LONDON (Reuters) - Sanofi's new bowel cancer drug Zaltrap is not worth using on Britain's state health service given its high price, the country's healthcare cost watchdog said on Friday. The National Institute for Health and Clinical Excellence (NICE) said the medicine was clinically effective but it could not be considered a cost-effective use of National Health Service resources - even though Sanofi offered a discount. The draft decision, which is now open to consultation, will be a disappointment for the French drugmaker and its U.S. biotech partner Regeneron Pharmaceuticals. ...

Source: You are not allowed to view links. Register or Login